FHIP1B Gene Biomedical Dossier
### **Gene Dossier: FHIP1B**

**Gene Identity & Clinical Context**
*   **HGNC ID**: 25378
*   **OMIM Gene ID**: 620229
*   **Primary Disease Associations**: Currently, there are no definitive disease associations listed in OMIM for *FHIP1B*. However, it is associated with conditions like Spastic Paraplegia 50 (Autosomal Recessive) in some databases, though this link requires further evidence.
*   **Clinical Significance Level**: Evidence for disease association is currently limited or emerging; not yet classified as definitive or strong.
*   **Inheritance Patterns**: The potential disease associations suggest autosomal recessive inheritance, but more clinical data is needed for confirmation.

**Constraint & Variant Intolerance**
*   **pLI, LOEUF**: Specific constraint scores from gnomAD for *FHIP1B* are not readily available in the search results. Generally, a pLI score >0.9 indicates intolerance to loss-of-function (LoF) variants. A low LOEUF score (e.g., <0.35) also signifies strong intolerance to LoF variation.
*   **Clinical Interpretation of Constraint Scores**: High pLI and low LOEUF scores suggest a gene is essential for normal function and that heterozygous protein-truncating variants (PTVs) are likely to be pathogenic, often associated with dominant disorders. The absence of such scores for *FHIP1B* may imply it is more tolerant of variation or that data is insufficient.
*   **Variant Classes Most Likely to be Pathogenic**: For genes intolerant to variation, protein-truncating variants (nonsense, frameshift, and canonical splice site variants) are most likely to be pathogenic. Missense variants in functionally critical domains can also be causative.

**Phenotype Spectrum & HPO Terms**
*   **Primary HPO terms**: As there is no strongly established disease link, a definitive list of HPO terms is not available. Phenotypes are typically documented through sources like OMIM, Orphanet, and DECIPHER.
*   **Secondary HPO terms**: Without established clinical cases, secondary, less common phenotypes are not defined.
*   **Age of Onset Patterns**: Information regarding the typical age of onset for *FHIP1B*-related disorders is not currently established in the literature.
*   **Phenotype Severity Spectrum**: The spectrum of severity (mild, moderate, severe) for phenotypes associated with *FHIP1B* variants is not yet characterized.

**Genotype-Phenotype Correlations**
*   **Variant Classes and Typical Phenotypes**: There are currently no well-established correlations between specific classes of *FHIP1B* variants and distinct clinical phenotypes.
*   **Protein Domain-specific Phenotype Patterns**: The functional domains of the FHIP1B protein have not yet been linked to specific phenotypic outcomes.
*   **Genotype-Phenotype Correlation Strength**: The strength of any genotype-phenotype correlation for *FHIP1B* is currently considered weak or unestablished due to a lack of sufficient clinical data.
*   **Examples**: No specific variant-to-phenotype examples are consistently reported in clinical databases or literature.

**Clinical Variants & Phenotype Associations**
*   ClinVar does not currently list pathogenic or likely pathogenic variants for *FHIP1B* with sufficient evidence and detailed phenotype associations for inclusion here. Information on specific rsIDs or HGVS nomenclature linked to clear phenotypes is sparse.

**Tissue Expression & Clinical Relevance**
*   **Highest Expressing Tissues (GTEx TPM)**: According to the Genotype-Tissue Expression (GTEx) portal, gene expression can vary significantly across tissues, which can suggest its functional importance in those locations. Specific TPM values for *FHIP1B* need to be queried directly from the GTEx database.
*   **Tissue-specific Phenotypes Expected**: High expression in certain tissues can imply that pathogenic variants might manifest with phenotypes related to those tissues. For example, high expression in the brain could suggest neurological phenotypes.
*   **Expression During Development and Age-related Phenotypes**: Gene expression during fetal development can be critical. Data from developmental tissue expression atlases would be needed to correlate *FHIP1B* variants with potential congenital or age-related phenotypes.

**Molecular Mechanism & Phenotype Pathways**
*   **Normal Gene Function**: The FHIP1B protein is a component of the FTS/Hook/FHIP (FHF) complex, which is involved in vesicle trafficking and the perinuclear distribution of the AP-4 complex and its cargo.
*   **Disease Mechanism**: For genes where LoF variants are pathogenic, haploinsufficiency is a common disease mechanism. However, the specific mechanism for *FHIP1B* (e.g., haploinsufficiency, dominant-negative) has not been determined.
*   **Cellular/Molecular Pathways Disrupted â†’ Phenotype Consequences**: Disruption of the FHF complex and vesicle trafficking could impair endosome organization and the proper sorting of cellular components, potentially leading to a wide range of cellular dysfunctions.
*   **Protein-protein Interactions Relevant to Phenotype**: FHIP1B interacts with FTS, HOOK proteins, and the HOPS complex to mediate its function in trafficking. It also interacts with AP-4 and its cargo ATG9A.

**Diagnostic Yield & Clinical Utility**
*   **Diagnostic Yield in Clinical Cohorts**: The diagnostic yield of sequencing *FHIP1B* in clinical cohorts is currently unknown, as it is not a well-established disease gene.
*   **Most Common Reasons for Testing This Gene**: Testing for this gene would likely occur in a research context or as part of a broad exome/genome analysis for patients with unexplained, potentially complex neurodevelopmental disorders.
*   **Clinical Actionability and Management Implications**: There is currently no information on clinical actionability or specific management guidelines related to *FHIP1B* variants.
*   **Genetic Counseling Considerations**: Counseling would be based on general principles, focusing on the uncertainty of the findings, the possibility of autosomal recessive inheritance, and the potential for variable expressivity if a disease link is eventually established.

**Key Clinical Literature & Studies**
*   There are no key clinical papers from 2020-2025 or landmark historical studies that have established a definitive genotype-phenotype correlation for *FHIP1B* in human disease. The available literature primarily focuses on its molecular function in cellular trafficking pathways.

**HPO-Variant Matching Summary**
*   **High-confidence HPO-variant associations**: At present, there are no high-confidence associations between specific HPO terms and pathogenic variants in *FHIP1B*.
*   **Phenotype red flags**: Due to the lack of a defined clinical syndrome, there are no established "red flag" HPO terms that would strongly suggest a pathogenic variant in this gene.
*   **Differential Diagnosis Considerations**: If future research links *FHIP1B* to a specific phenotype (e.g., spastic paraplegia), the differential diagnosis would include other genes known to cause similar conditions.

